Nexstim Oyj (OHEL:NXTMH) Total Liabilities: €8.03 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OHEL:NXTMH Nexstim Oyj OHEL:NXTMH
61 GF Score
Price €10.80
GF Value €9.38
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Nexstim Oyj Total Liabilities?

Nexstim Oyj OHEL:NXTMH +8.22% 61 Total Liabilities is €8.03 Mil as of Jun. 2026. GuruFocus rates OHEL:NXTMH with a GF Score™ of 61/100 and a GF Value™ of €9.38 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Nexstim Oyj's Total Liabilities for the quarter that ended in Jun. 2026 was €8.03 Mil.

Nexstim Oyj's quarterly Total Liabilities declined from Jun. 2025 (€9.17 Mil) to Dec. 2025 (€8.98 Mil) and declined from Dec. 2025 (€8.98 Mil) to Jun. 2026 (€8.03 Mil).

Nexstim Oyj's annual Total Liabilities increased from Dec. 2023 (€7.05 Mil) to Dec. 2024 (€10.50 Mil) but then declined from Dec. 2024 (€10.50 Mil) to Dec. 2025 (€8.98 Mil).

Nexstim Oyj Total Liabilities Historical Data

* Premium members only.

The historical data trend for Nexstim Oyj's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nexstim Oyj Total Liabilities Chart

Nexstim Oyj Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.84 6.15 7.05 10.50 8.98

Nexstim Oyj Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.32 10.50 9.17 8.98 8.03
OHEL:NXTMH
61GF Score
Nexstim Oyj OHEL:NXTMH
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nexstim Oyj Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Nexstim Oyj's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.884+(2.558+0.539
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=8.98

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=13.163-4.182
=8.98

Nexstim Oyj's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.676+(2.002+0.35
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=8.03

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=16.473-8.445
=8.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €8.03 Mil mean?
Nexstim Oyj (OHEL:NXTMH) has a Total Liabilities of €8.03 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Nexstim Oyj and its competitors.
Is Nexstim Oyj's Total Liabilities too high?
Nexstim Oyj's current Total Liabilities is €8.03 Mil. Overall, Nexstim Oyj has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nexstim Oyj's Total Liabilities compare to ABT and SYK?
Nexstim Oyj's Total Liabilities of €8.03 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Nexstim Oyj and its competitors. Nexstim Oyj's current Total Liabilities is €8.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexstim Oyj stock overvalued right now?
Based on GuruFocus' analysis, Nexstim Oyj (OHEL:NXTMH) is currently considered Modestly Overvalued. The stock's GF Value™ is €9.38, compared to a current price of €10.80 — trading 15.1% above its estimated fair value. The current Total Liabilities is €8.03 Mil. Nexstim Oyj's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Nexstim Oyj (OHEL:NXTMH), the current Total Liabilities is €8.03 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nexstim Oyj (OHEL:NXTMH) Overvalued in 2026?

Based on GuruFocus' analysis, Nexstim Oyj stock appears to be overvalued. The current stock price of €10.80 is trading 15.1% above its estimated GF Value™ of €9.38. GuruFocus considers Nexstim Oyj to be Modestly Overvalued.

Key valuation signals for OHEL:NXTMH:

  • Total Liabilities: €8.03 Mil
  • GF Value™: €9.38 vs. price of €10.80 (15.1% above fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the OHEL:NXTMH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nexstim Oyj Business Description

Other Exchanges 5NX:Germany
Address Elimaenkatu 9 B, Helsinki, FIN, 00510
Nexstim Oyj is a Finnish medical technology company. It has developed a non-invasive brain-stimulation technology for navigated transcranial magnetic stimulation (nTMS), with sophisticated 3D navigation that provides accurate, personalized targeting of TMS to specific brain areas. The company's diagnostic business focuses on commercializing the NBS System 6, an FDA-cleared, CE-marked navigated TMS system for pre-surgical mapping of the brain's speech and motor cortices. Its therapy business sells the NBS System 6 for the treatment of depressive disorder in the United States, and for the treatment of depression, chronic neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb, in Europe. Geographically, the firm generates maximum revenue from North America.
61GF Score

Get the complete analysis for OHEL:NXTMH

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.80
Price
€9.38
GF Value